Sotera Health (NASDAQ:SHC) Shares Purchased by Maverick Capital Ltd.

Maverick Capital Ltd. boosted its position in Sotera Health (NASDAQ:SHC) by 3.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,497,367 shares of the company’s stock after purchasing an additional 118,353 shares during the quarter. Maverick Capital Ltd. owned about 1.23% of Sotera Health worth $58,406,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Darsana Capital Partners LP increased its stake in shares of Sotera Health by 716.9% in the 3rd quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock worth $334,167,000 after acquiring an additional 17,560,636 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Sotera Health by 27.0% during the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock worth $145,863,000 after acquiring an additional 2,579,248 shares in the last quarter. Sessa Capital IM L.P. raised its position in shares of Sotera Health by 46.5% during the 3rd quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after acquiring an additional 2,000,000 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Sotera Health by 18.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,348,917 shares of the company’s stock worth $22,527,000 after acquiring an additional 208,914 shares in the last quarter. Finally, William Blair Investment Management LLC raised its position in shares of Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock worth $13,430,000 after acquiring an additional 6,707 shares in the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SHC. Barclays raised their target price on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research report on Thursday, November 21st. Finally, Citigroup lifted their price target on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.50.

Sotera Health Stock Up 0.5 %

SHC opened at $13.17 on Friday. The business’s fifty day moving average is $15.25 and its two-hundred day moving average is $14.01. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a market cap of $3.73 billion, a price-to-earnings ratio of 52.68 and a beta of 2.08. Sotera Health has a one year low of $10.71 and a one year high of $17.44.

Sotera Health (NASDAQ:SHC) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The company had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. During the same quarter in the prior year, the company earned $0.18 earnings per share. The firm’s revenue was up 8.5% compared to the same quarter last year. Analysts anticipate that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. This represents a 16.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 55.12% of the company’s stock.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.